Searched for
BIO SIMILAR DRUGS
Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...- OpenAI backs startup aiming to block AI-enabled bio weaponsOpenAI is the lead investor in a $15 million seed round in Red Queen Bio, which is trying to make sure the AI industry's defenses are growi...
- ET MSME Awards 2025: India's pharma MSMEs face existential choiceNew bio-equivalence rules promise safer drugs but could eliminate pharma manufacturers that make medicines affordable. Is there a middle gr...
- Zydus moves Delhi HC against order restraining manufacture, sale of its cancer drugZydus Lifesciences has appealed a Delhi High Court order. The order restricts it from producing a biosimilar of E.R. Squibb's Nivolumab. Sq...
- Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapyThe deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...
- Swiss drugs regulator approves Moderna’s COVID-19 vaccineSwitzerland has been a second-wave coronavirus hotspot, with infections totalling some 500,000 and deaths rising by dozens daily to more th...
- Lupin Pharma gets Good Manufacturing Certificate for its biologic plantBiosimilar Etanercept is used to fight a range of severe auto-immune disorders.
- Roche, Emcure may end pact to make 2 blockbuster drugsEmcure is still the distributor for those two drugs in India. Roche had handed out the manufacturing and marketing of trastuzumab and ritux...
- Pharma incubators at state-owned research institutions soonnullDisclosing this at BIO Asia International 2017 in Hyderabad on Wednesday, Union commerce joint secretary Sudhanshu Pandey, also said th...
- Germany bans 80 generic drugs for insufficient trials by GVKThe regulator said it had informed the drugs manufacturers about its decision on Monday and the ban on the sales of medicines came into eff...
- GVK Bio manipulated clinical trials of generic drugs: ReportsThe Federal Institute for Medicines and Medical Products, which issues the licences in Germany, confirmed it has been investigating the all...
- Rail and road transport plan big push for bio-dieselRailways has decided to power a fleet of 4,000 locomotives with alternative fuels such as bio-diesel as an attempt to move towards a cleane...
- Biocon breast cancer drug too expensive, say health activistsBiocon’s launch of the world’s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big wa...
- Drug regulator asks Sun Pharma to halt clinical research at Mumbai laboratoryThe drug regulator took the step after discovering that Sun didn’t have the requisite approval from the central government for operating th...
- Biologics worth $50 bn to lose patent protection in USA:Report"It is estimated that between 2009 and 2019, 21 biologics with a market value of over $ 50 billion will lose patent protection in the US al...
- Cipla to invest Rs 500 cr to set up API facilitiesCipla Ltd plans to invest Rs 500 crore for setting up an active pharmaceutical ingredients (API) facilities at Patalganga, Bengaluru and Ku...
- Biosimilar products development gets a USFDA norms boostA biosimilar is a product that is similar to a biologic, which in turn is any drug produced through a biological route rather than chemical...
- Biocon at lifetime peak, stock surges 11 pc on BSEBiotechnology firm Biocon today shot up by over eleven per cent to an all-time high of Rs 447.90 on the Bombay Stock Exchange.
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
- US health bill to benefit local generic firmsThe US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promis...
Load More
